FAM
PRVL

Fred Alger Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Fred Alger Management’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,000
Closed -$47K – 606
2019
Q4 		$47K Buy
+3,000
New +$38.3K ﹤0.01% 432

Other funds holding PRVL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fred Alger Management's PRVL Position: Q1 2020 in Review

Fred Alger Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2020, closing a stake of 3,000 shares — an estimated $47K sold.

Fred Alger Management first reported a position in PRVL in Q4 2019 and held it in 1 quarter. The position peaked at $47K in Q4 2019. 58 funds tracked by Wall St. Rank hold PRVL as of Q1 2020.

  • Fred Alger Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Fred Alger Management sold 3,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2020, an estimated $47K.
  • Fred Alger Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Fred Alger Management's Prevail Therapeutics Inc. Common Stock position peaked at $47K in Q4 2019.
  • 58 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2020.

Based on Fred Alger Management's 13F filing for Q1 2020, filed 15 May 2020.